Scholar Rock

Targeting growth factors

Cells produce protein growth factors in the precursor, or latent, form. For the mature growth factor to carry out its function, it must be activated (through molecular events) and separated from the prodomain.

Scholar Rock monoclonal antibodies target the prodomain of the precursor, or latent form of growth factors, and block the cage’s lock to inhibit activation. Given the much greater structural differences of the prodomain, we leverage this variance to achieve extraordinary selectivity.

With greater selectivity, we aim to minimize toxicity that have challenged approaches that target the mature form of growth factors.

LEARN MORE: Scholar Rock


Inhibiting latent TGFβ

WIKIMEDIA: European Bioinformatics Institute

Selective inhibitors of TGFβ1

While TGFβ is at the apex of the fibrotic signaling cascade, there are safety concerns linked to off-target effects of neighboring growth factors by non-selective approaches.

Scholar Rock identified potent and selective inhibitors of TGFβ1 signaling at the source of disease in the tissue microenvironment. Preclinical studies show that these highly specific inhibitors can prevent the activation of the growth factor in the fibrotic matrix and may offer a powerful new approach to suppressing pro-fibrotic signaling in multiple organs.

Scholar Rock is collaborating with Gilead with the aim of selecting molecules to be developed as new medicines for patients with fibrotic diseases.

LEARN MORE: Scholar Rock